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Abstract 
Background: Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) selectively eliminates tumor cells. 
However, the short biological half‑life of this molecule limits its potential use in the clinic. Our aim was to construct a 
recombinant strain of nonpathogenic Lactococcus lactis bacteria as a vector for effective and prolonged human TRAIL 
production. Herein, we examined the expression and secretion conditions leading to the production of biologically 
active protein in vitro.
Results: The human soluble TRAIL‑cDNA (hsTRAIL‑cDNA) with optimized codons was designed to fit the codon 
usage pattern (codon bias) of the L. lactis host. This cDNA construct was synthesized and cloned in lactococcal plas‑
mid secretion vector pNZ8124 under the control of the nisin‑induced PnisA promoter. The pNZ8124‑hsTRAIL plasmid 
vector was transformed into the L. lactis NZ9000 host strain cells by electroporation. Secretion of the protein occurred 
at the neutral pH during induction, with optimized concentration of the inducer and presence of serine proteases 
inhibitor. Using Western blotting and amino acid sequencing method we found that TRAIL was secreted in two forms, 
as visualized by the presence of two distinct molecular size bands, both deprived of the usp45 protein, the bacte‑
rial signal peptide. By the use of MTS assay we were able to prove that hsTRAIL present in supernatant from L. lactis 
(hsTRAIL+) broth culture was cytotoxic to human HCT116 colon cancer cells but not to normal human fibroblasts. 
Flow cytometry analysis revealed TRAIL‑induced apoptosis of cancer cells.
Conclusions: We designed recombinant L. lactis bacteria, which efficiently produce biologically active, anti‑tumori‑
genic human TRAIL in vitro. Further studies in tumor‑bearing NOD‑SCID mice will reveal whether the TRAIL‑secreting 
L. lactis bacteria can be used as a safe carrier of this protein, capable of inducing effective elimination of human colon 
cancer cells in vivo.
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Background
Colorectal cancer is one of the most common gastro-
intestinal cancers worldwide [1]. The standard treat-
ment, which includes surgery followed by chemotherapy 
often induces drug resistance of tumor cells and tumor 
relapse. Therefore the need for a novel form of a more 
effective treatment is still urgent [2]. Tumor necrosis 
factor-related apoptosis-inducing ligand [3, 4] (TRAIL, 
other names: TNFSF10; CD253; Apo-2L; TNLG6A [5]), 
is a protein belonging to the TNF-superfamily [6] and 
has been shown in in vitro and in vivo models to induce 
apoptosis of various types of cancer cells while sparing 
normal ones [7]. TRAIL may act as a trans-membrane 
protein or can be cleaved from the cell surface by cath-
epsin E to form a soluble ligand. Both forms of TRAIL 
are biologically active and their interactions with specific 
death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) 
induce apoptosis of cancer cells upon activation of cas-
pase-8 [4, 8]. The only form of human TRAIL approved 
currently for the use in clinical trials is its recombinant 
soluble and untagged version—dulanermin (Apo2L.0, 
AMG-951), developed by Genentech [9]. Dulanermin 
has been tested in combination with different cytostatic 
drugs in phase I-clinical studies concerning colorectal 
cancer patients, in which it proved to be safe, however, 
with limited activity because of its low pharmacokinetic 
profile [10–12]. Therefore, recent research on the new 
TRAIL formulations was focused on enhancing its bio-
activity for cancer treatment and increasing its stability in 
humans [10].
Lactococcus lactis is a non-pathogenic, Gram-pos-
itive bacterium, for years widely used in dairying. 
Because of its safety and potential for direct secretion 
(monolayer cell wall) of heterologous proteins into 
the extracellular environment [13], it gained an inter-
est as a host for production of recombinant proteins, 
including therapeutics [14], especially after the devel-
opment of the Nisin Controlled Gene Expression Sys-
tem  (NICE®). This solution guaranteed, among others, 
tightly controlled, endotoxin-free and without for-
mation of inclusion bodies, food-grade expression of 
proteins [15]. The role of L. lactis bacteria in potential 
treatment of colorectal cancer is worth noticing, since 
lactic acid bacteria (LAB) are common microflora of 
the gut’s ecosystem and, therefore, present the possibil-
ity of introducing therapeutic proteins locally. Recently, 
Zhang et al. showed the ability of recombinant L. lactis 
NZ9000 strain to produce KiSS-1 peptide, a cancer sup-
pressor factor, which inhibited proliferation and migra-
tion of human colon cancer HT-29 cells in  vitro [16]. 
In our study we propose L. lactis bacteria as the host 
for an efficient expression of a secretory bioactive form 
of human TRAIL (human soluble TRAIL; hsTRAIL) 
under the control of the nisin-induced PnisA promoter, 
which would enable elimination of human colorectal 
cancer HCT116 cells in vitro and in vivo. In this paper 
we focused on optimization of the culture and secre-
tion conditions for recombinant L. lactis strain, leading 
to the production of biologically active protein. To the 
best of our knowledge, this is the first study providing 
evidence that genetically engineered L. lactis bacteria, 
harbouring a plasmid with hsTRAIL-cDNA, may be 
an applicable carrier for efficient expression, secretion 
and safe delivery of bioactive hsTRAIL for elimination 
in vitro of colorectal cancer cells.
Results
Lactococcus lactis (hsTRAIL+) bacteria require specific 
conditions for growth and efficient expression 
of recombinant hsTRAIL
For the most effective expression of recombinant 
hsTRAIL in L. lactis bacteria, we designed a synthetic 
hsTRAIL-cDNA with optimized codons to fit the 
codon usage pattern (codon bias) of L. lactis as the host 
[18–20]. To ensure an efficient secretion of hsTRAIL 
by recombinant bacteria, we used a plasmid vector 
pNZ8124 containing the signal sequence of the lacto-
coccal major secreted protein usp45, located down-
stream of the nisin-inducible PnisA promoter (Fig.  1). 
The two-step screening of L. lactis clones after elec-
troporation revealed clone number 3 (Fig. 2), as the one 
harbouring pNZ8124 plasmid with hsTRAIL-cDNA. 
This clone was designated as L. lactis (hsTRAIL+) and 
selected for further studies. Subsequently, we optimized 
the culture conditions for hsTRAIL-producing L. lactis 
clone. For this reason we determined how the combi-
nation of glucose and l-arginine, as sources of energy 
may affect both density and pH of L. lactis (hsTRAIL+) 
culture after 4 and 24  h of their static growth. We 
observed that only the combination of 0.3% glucose and 
0.3% of l-arginine enabled satisfactory bacterial culture 
density  (OD600) and neutral pH over time (Fig. 3). This 
combination of glucose and l-arginine concentrations 
was selected for further studies.
One of the critical steps in the  NICE® expression sys-
tem is the amount of nisin added as the inducer of pro-
tein expression [15]. In the study performed by Miereau 
et al., the authors showed a strong correlation between 
the cell density at the time of induction and the amount 
of nisin required to obtain maximal induction rate [17]. 
Therefore, we also examined the effect of different con-
centrations of nisin on hsTRAIL expression by L. lactis 
(hsTRAIL+) and found 25 ng/ml as the most effective 
(Fig. 4). This concentration was used in further studies.
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L. lactis (hsTRAIL+) bacteria secrete hsTRAIL 
into the culture supernatant
In the next step, using Western blot we confirmed the 
presence of hsTRAIL in the supernatant from L. lac-
tis (hsTRAIL+) broth culture. TRAIL secretion was 
detected already during the first hour upon induction 
with nisin, being most effective after 3–4 h (Fig. 5a). Sur-
prisingly, Western blot results revealed that the TRAIL 
protein appeared in the form of two separate bands and 
those remained intact for at least 4  h. The subsequent 
Fig. 1 Schematic presentation of the TRAIL protein structure and map of the pNZ8124 secretion vector with expression cassette for controlled 
hsTRAIL production. a Left—TRAIL is a type II transmembrane protein composed of three major parts: an extracellular TNF‑like domain (38–281 
aa) with receptor binding region (114–281 aa) and cysteine residue (Cys230), which together with zinc ion are essential for the interaction 
between three TRAIL‑molecules and formation of active TRAIL‑homotrimer; a transmembrane domain (18–38 aa) and small cytoplasmic domain 
(1–18 aa). Transmembrane TRAIL‑ligand might be cleaved at an extracellular stalk and released as a soluble molecule. Both forms of TRAIL‑ligand 
(membrane‑bound and soluble) are active. Modified from [42]. Right—codon‑optimized hsTRAIL‑cDNA sequence (coding the region 114–281 aa 
of human TRAIL) was inserted into pNZ8124 vector plasmid and transformed into L. lactis NZ9000 host strain cells via electroporation. The hsTRAIL 
expression was based on the Nisin Controlled Gene Expression System  (NICE®) with nisin as the inducer. Protein secretion into the medium was 
obtained by the presence of sequence for signal peptide of L. lactis usp45 gene (usp45) downstream from promoter region (PnisA). b The pNZ8124 
vector contains region for the nisin‑inducible promoter (PnisA), an origin of replication sequence (ORI), two genes for the replication proteins (repA, 
repC), the transcription termination sequence (T) and the gene for the resistance to chloramphenicol (Cm) as the selection marker. The cDNA for 
hsTRAIL was inserted downstream of the promoter region and the signal sequence for usp45 gene (SP usp45) on the plasmid, between EcoRV and 
XbaI sites from the multicloning site sequence (MCS). The secretion vector with hsTRAIL‑cDNA insert has no any tag sequence added. The vector 
map is not drawn in scale
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amino acid sequence-mass spectrometry sequenc-
ing of protein content in the upper and bottom TRAIL 
bands, revealed that in both bands TRAIL protein occurs 
beyond any doubt (Table 1) and in both TRAIL fractions 
the usp45 leader peptide (27 aa) was cut off. Furthermore, 
in the upper TRAIL band, additional 9 amino acids from 
the N-terminus were also cleaved to form the TRAIL 
molecule consisting finally of 160 aa. In the bottom band 
only one peptide-spectrum match (PSM) in the sequence 
range of 37–45 aa and 48–57 aa were identified in com-
parison to 4 and 9 PSMs measured respectively for upper 
band (Table 2). Identification of a single PMS can result 
from a contamination/streaking during electrophoretic 
separation or the 37–57 aa sequence was detected only in 
the small fraction of protein molecules present in bottom 
band. Molecular weights of 18,513 Da and 15,608 Da cor-
responding to measured fragments of hsTRAIL for upper 
and bottom band, respectively (Fig. 6), are in good agree-
ment with masses observed in SDS-PAGE electropho-
resis (Fig. 5b). It seems that in the bottom TRAIL band, 
37 amino acids were cut off from the N-terminus of the 
TRAIL polypeptide to form a more truncated form, con-
sisting of 132 aa.   
Aprotynin does not affect proteolysis of secreted hsTRAIL
Heterologous proteins produced by bacterial expression 
systems are exposed for cleavage by extracellular pro-
teases. The most common proteases in L. lactis bacteria, 
which might affect the secretion of recombinant proteins 
are serine proteases [18–21]. Therefore, in the next set of 
experiments, to check if the two forms of our hsTRAIL 
could be a result of the action of bacterial extracellular 
proteases, we initiated the expression and secretion of 
TRAIL in the presence of aprotynin—serine proteases 
inhibitor. We observed, that addition of aprotynin influ-
enced only the intensity of the bands corresponding to 
the two forms of TRAIL, but did not affect their presence 
(Fig.  7). Since the signals for both TRAIL bands were 
most intensive when aprotynin was used at the concen-
tration of 2 µg/ml, this was selected for further studies.
Fig. 2 Selection of L. lactis (hsTRAIL+) clones. Left—results of DNA electrophoretic separation of PCR reaction products. As templates for PCR 
reaction, plasmids isolated from L. lactis recombinant clones (∆1–∆6), were used. White arrow‑ sequence for hsTRAIL (438 bp) presents in selected L. 
lactis clone ∆3. Right—results from DNA electrophoresis for hsTRAIL‑insert after digestion of isolated plasmids with EcoRV and XbaI (on the left) and 
after PCR reaction with digested inserts used as the templates (on the right). White arrow—sequence for hsTRAIL (438 bp) presents in selected L. 
lactis clone ∆3. M‑DNA molecular weight marker;  V124—plasmid vector pNZ8124 without hsTRAIL‑insert (negative control)
Fig. 3 Optimization of growth conditions for L. lactis (hsTRAIL+) 
bacteria. L. lactis (hsTRAIL+) bacteria were cultured in M17 broth 
medium supplemented with chloramphenicol (10 µg/ml) and 
different concentration of glucose or/and l‑arginine, as the source 
of energy. After 4 and 24 h of culture, pH (y‑axis) and optical density 
at 600 nm (OD600; indicated by the numbers) were measured. For 
further experiments, the combination of glucose and l‑arginine at 
0.3% both, was selected. Experiment was performed three times, 
each in triplicates and mean values ± SD are presented
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hsTRAIL is efficiently secreted to the broth culture 
supernatant by L. lactis (hsTRAIL+)
One of the major advantage of NICE expression system 
is secretion of recombinant protein into the medium. 
To calculate the efficacy of hsTRAIL secretion, when 
pNZ8124 plasmid vector with sequence for usp45 leader 
peptide was used, we performed ELISA and quantified 
the concentration of the protein both in crude superna-
tants and cell lysates after 4 h upon the nisin-induction. 
The hsTRAIL was mostly presented in supernatants from 
broth culture of L. lactis (hsTRAIL+), where achieved 
the mean concentration of 97.4  ng/ml (Fig.  8). For cor-
responding cell lysates, the mean hsTRAIL concentration 
achieved 10.97 ng/ml, indicating the mean secretion effi-
cacy at 89.87% (± SD 95.34; 84.41). The concentration of 
hsTRAIL in supernatants and lysates from negative con-
trol was negligible. Further use of the protein centrifu-
gal concentrators enabled efficient diafiltration of crude 
supernatant from L. lactis (hsTRAIL+) broth culture and 
concentration of TRAIL sample 10- to 20-fold.
hsTRAIL produced by L. lactis (hsTRAIL+) retains its 
biological activity and induces apoptosis of human colon 
cancer cells in vitro
To assess, if hsTRAIL present in broth supernatants from 
L. lactis (hsTRAIL+) culture is biologically active and 
possess antitumor activity in vitro, we used human colon 
cancer HCT116 cells incubated with increasing concen-
trations of L. lactis derived-hsTRAIL. Human cardiac 
fibroblasts, as representatives of rapidly proliferating nor-
mal cells were used as a control in parallel. As a positive 
control, commercially available recombinant TRAIL was 
used at the same range of concentrations. Cancer and 
normal cells were incubated either with broth culture 
supernatant or standard TRAIL preparation for 48  h 
and their viability was evaluated by MTS assay, which 
determines activity of mitochondrial enzyme—succinate 
dehydrogenase. In living cells, this enzyme converts yel-
low tetrazole (MTS) into blue formazan, therefore the 
absorbance signal is proportional to the number of liv-
ing cells. The obtained results (Fig. 9a) document that in 
contrast to fibroblasts, for which hsTRAIL did not show 
any cytotoxicity, a decreasing viability of cancer cells, 
alongside with increasing concentration of the produced 
hsTRAIL, was detected. In keeping, control supernatant 
from the broth culture of L. lactis mock transfected, har-
bouring a plasmid vector without TRAIL-cDNA insert—
L. lactis (hsTRAIL−) did not affect viability of colon 
cancer HCT116 cells (Figs. 9b, 10). These results proved, 
that hsTRAIL, produced by selected clone of L. lactis 
bacteria, remains biologically active and selectively kills 
colon cancer cells in vitro. Moreover, comparison of the 
antitumor activity of hsTRAIL from the supernatant of 
L. lactis (hsTRAIL+) culture, with the same concentra-
tions of TRAIL, as of the commercially available human 
TRAIL preparation has shown that our hsTRAIL pos-
sesses the same biological activity against tumor cells as 
the standard (Fig.  10). Since TRAIL eliminates cancer 
cells via extrinsic apoptotic pathway, we examined the 
effect of L. lactis-derived hsTRAIL on HCT116 apopto-
sis (Fig. 11). Flow cytometry analysis showed that 30% of 
HCT116 cells were apoptotic after treatment with super-
natant from L. lactis (hsTRAIL+) bacteria, similarly to 
positive control (Fig.  11a, e), in contrast to non-treated 
cells (Fig.  11a, b) or cells incubated with supernatant 
from L. lactis (hsTRAIL−) (Fig. 11a, c).
Discussion
The use of TRAIL in the clinic is of great hope because 
of its selective action against malignant cells. Another 
potential clinical advantage of TRAIL is its synergism 
with some chemotherapeutics currently in use, which 
may enable decreasing of their dose, thus reducing side 
effects. This might improve not only prognosis, but also 
patients’ quality of life. Therefore, the current research is 
focusing on new TRAIL-formulation and delivery strat-
egies, helping to overcome the problem with its short 
biological half-life in humans. Part of these new strate-
gies represent, among others, bacterial expression sys-
tems. In 2010, Zhang et  al. showed that tumor-bearing 
mice injected intravenously with E. coli producing 
human recombinant TRAIL, localized and replicated 
in tumor tissues of murine B16 melanoma, its metasta-
ses and human H460 lung carcinoma [22]. The observed 
bioactivity of TRAIL and tumor tropism of E. coli might 
classify this model as ideal for specific tumor targeting 
immunotherapy. However, when using E. coli for delivery 
Fig. 4 Optimization of hsTRAIL expression by L. lactis (hsTRAIL+) 
using the Nisin Controlled Gene Expression System  (NICE®). 
TRAIL‑protein was precipitated from supernatants from broth cultures 
of L. lactis (hsTRAIL+), induced for hsTRAIL expression with different 
concentrations of nisin. The samples were subjected to SDS‑PAGE 
electrophoresis and Western blot analysis. As a negative control (NC) 
supernatant from non‑induced broth cultures of L. lactis (hsTRAIL+) 
was used in parallel. For further experiments, the nisin concentration 
of 25 ng/ml was selected. NC—negative control; 10–80 (ng/
ml)—concentration of nisin used for the induction. Data from one 
representative experiment out of three performed are shown
Page 6 of 16Ciaćma et al. Microb Cell Fact          (2018) 17:177 
of therapeutics in  vivo, there is still a risk of complica-
tions, including bacteremia or even endotoxic-shock. 
Problem of the formation of insoluble inclusion bod-
ies during overexpression of recombinant TRAIL by 
E. coli has been also shown in some recent studies [23, 
24]. Another examined bacterial vector for TRAIL was 
attenuated Salmonella typhimurium, which besides pro-
duction of bioactive protein, has shown activation of the 
immune system of BALB/c nude mice [25]. However, 
S. typhimurium is mainly intracellular bacterium, thus 
might reduce the efficiency of the produced TRAIL act-
ing with specific membrane receptors on target cells.
Lactococcus lactis NZ9000 strain has been used for pro-
duction of many biologically active proteins, assuming its 
potential use in future therapies, e.g. IL-12—in the treat-
ment of asthma [26], IL-10 and TGF-β1—inflammatory 
Fig. 5 Detection of hsTRAIL protein production and secretion by L. lactis (hsTRAIL+). a hsTRAIL was detected in supernatants from broth cultures 
of L. lactis (hsTRAIL+) by Western blot and appeared in two bands indicating 160 aa (122–281) hsTRAIL molecule without usp45 leader peptide 
and devoids of 9 amino acids from N‑terminus (upper band) and more truncated hsTRAIL ligand with 132 aa (150–281; lower band). Secretion 
of hsTRAIL started within the first hour after beginning of the induction with nisin (25 ng/ml). M—molecular weight marker; rhTRAIL (PeproTech, 
London, UK)—recombinant human TRAIL used as positive control; NC—protein sample precipitated from supernatant of L. lactis (hsTRAIL−) culture 
used as the negative control. Data from one representative experiment out of five performed are shown. b Concentrated supernatants of broth 
culture of L. lactis (hsTRAIL±) bacteria or precipitated proteins from supernatants were subjected to SDS‑PAGE electrophoresis and  SYPRO® Ruby 
Protein Gel staining. M—marker; “‑”—blank space; Sup.—supernatant; rhTRAIL—recombinant human TRAIL used as positive control; A—hsTRAIL 
“upper”; B—hsTRAIL “lower” band; PREP.—precipitation using chloroform–methanol method. Data from one representative experiment out of three 
performed are shown
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bowel disease (IBD) [27–29], insulin-like growth fac-
tor I (IGF-I)—colitis [30], recombinant mouse heme 
oxygenase-1 (rmHO-1) [31], and many others [32–34]. 
In cancer therapy, the potential use of L. lactis NZ9000 
strain concerned breast cancer, namely hemagglutinin-
neuraminidase (HN) protein of Newcastle disease virus 
(NDV) [35].
In our study we have documented the expression and 
secretion of bioactive human TRAIL by L. lactis NZ9000 
strain harbouring the plasmid containing cDNA for 
codon-optimized human soluble TRAIL. The step of 
codon-optimization was relevant since the codon usage 
is a key factor in assessing probability of successful and 
efficient expression of heterologous genes in L. lactis [15]. 
After selection of hsTRAIL-expressing clone, we opti-
mized conditions for the culture of L. lactis (hsTRAIL+) 
strain. Our results showed that cell density at the time 
of induction and the concentration of nisin added as the 
inducer, are most critical parameters. In the culture of 
lactic acid bacteria (LAB), the lactic acid fermentation is 
a dominant metabolic process of sugar conversion into 
cellular energy. The main, final fermentation product of 
this conversion is lactic acid which is toxic [36]. However, 
since the toxicity of lactic acid depends on its non-disso-
ciated form, increasing of pH of the medium for bacte-
rial culture allows to elongate the period of their growth. 
We showed, that supplementation of standard culture 
medium for L. lactis (hsTRAIL+) bacteria with l-argi-
nine, as additional source of energy, enables the main-
tenance of neutral pH. An efficient reduction of acidity 
and improvement of bacterial biomass, after arginine 
supplementation, has been shown recently by Laroute 
et al. [37]. This “buffering” effect of arginine results from 
the formation of ammonium ion in the route of arginine 
deiminase pathway [37]. Another important issue related 
to pH level of cell culture is ATR effect (acid tolerance 
Table 1 Parameters describing quality of  hsTRAIL 
identification in LC–MS/MS experiments
a Protein scores are derived from ions scores as a non-probabilistic basis for 
ranking protein hits
b Percentage of the sequence of the identified protein covered by the peptides 
matched
c Number of sequenced peptides matched to the protein
d Number of peptide-spectrum matches (PSMs)
Description Scorea Coverageb #  Peptidesc #  PSMsd
Upper band 10,405.62 73.98 17 372
Bottom band 9530.10 73.98 16 343
Table 2 List of peptides sequenced in LC–MS/MS experiments for upper and bottom band
a Ions score is − 10*Log(P) where p is the probability that the observed peptide match is a random event
Peptides identified in bottom band based on a single peptide-spectrum match (PMS) are marked in italics
Start–end Sequence Modifications # Missed 
cleavages
Upper band Bottom band
# PSMs Ion  scorea # PSMs Ion  scorea
37–45 VAAHITGTR 0 9 40 1 25
48–57 SNTLSSPNSK 0 4 39 1 38
65–73 KINSWESSR 1 28 64 26 64
66–73 INSWESSR 0 3 46 3 46
74–85 SGHSFLSNLHLR 0 105 69 85 64
86–94 NGELVIHEK 0 22 63 20 63
95–106 GFYYIYSQTYFR 0 16 52 15 66
95–112 FQEEIK 0 2 24 2 24
107–116 FQEEIKENTK 1 47 59 45 57
113–127 NDKQmVQYIYK M5 (oxidation) 1 31 63 5 65
117–127 NDKQMVQYIYK 1 1 49 25 63
120–127 QmVQYIYK M2 (oxidation) 0 22 47 21 48
120–127 QMVQYIYK 0 5 44 5 44
120–139 QmVQYIYKYTSYPDPILLmK M2 (oxidation); M19 
(oxidation)
1 1 40 0 0
128–139 YTSYPDPILLmK M11 (oxidation) 0 41 53 43 54
128–139 YTSYPDPILLMK 0 5 44 12 45
128–142 YTSYPDPILLmKSAR M11 (oxidation) 1 1 38 3 33
143–166 DAEYGLYSIYQGGIFELK 0 20 78 20 84
143–170 DAEYGLYSIYQGGIFELKENDR 1 7 92 9 105
171–196 IFVSVTNEHLIDmDHEASFFGAFLVG M13 (oxidation) 0 2 30 2 46
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response) [20], which suppression has been shown to 
improve the production level and stability of secreted 
recombinant proteins [20, 38]. We showed that suffi-
ciently high concentration of glucose, besides l-arginine, 
is also important, and only the combination of these two 
sources of energy in concentrations ≥ 0.3%, resulted in an 
optimal density of bacterial cell growth. The concentra-
tion of nisin, the inducer, as the second parameter [17] 
used for recombinant protein expression (NICE system), 
was established at 25  ng/ml, which occurred to be the 
lowest effective dose.
We observed that L. lactis (hsTRAIL+) strain produces 
human TRAIL in two separate forms, suggesting its 
enzymatic cleavage by bacterial proteases. The L. lactis 
proteolytic system involves two major proteases: intra-
cellular ClpP and an extracellular trypsin-like serine pro-
tease HtrA [28]. The standard role of HtrA is degradation 
of exported abnormal proteins. In the study performed by 
Poquet et al. [28], also working with the NICE system and 
L. lactis NZ9000 strain, two novel actions of this protein-
ase were observed and described, namely a pro-peptide 
processing of the native host proteins and their matura-
tion [18]. In further studies, the same authors described 
the role of HtrA proteinase in proteolysis of secreted 
recombinant proteins concluding, that the mutation 
of htrA gene leads to the stabilization of recombinant 
Fig. 6 Sequence coverage obtained for upper and bottom band in LC–MS/MS analysis. Red capital letters depicted amino acid (aa) sequence of 
peptides detected in upper and bottom TRAIL bands, black capital letters depicted aa sequence of peptides not detected in the both TRAIL bands, 
and black small letters depicted aa sequence of peptides detected only once in the bottom TRAIL band (Table 2). The upper and bottom TRAIL 
bands were obtained after SDS‑PAGE analysis of TRAIL secreted by L. lactis (TRAIL+) bacteria
Fig. 7 Effect of aprotynin on hsTRAIL secretion by L. lactis (hsTRAIL+). The presence of aprotynin during induction of hsTRAIL expression and 
secretion did not affect proteolysis of secreted hsTRAIL as detected by Western blot. M—molecular weight marker; rhTRAIL (PeproTech)—
positive control; NC—protein sample precipitated from supernatant of L. lactis (hsTRAIL−) culture as the negative control; 0; 2 and 5 (µg/ml)—
concentrations of aprotynin used during induction of protein expression with nisin (25 ng/ml). Data from one representative experiment out of five 
performed are shown
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proteins [19, 21]. From the other hand, Sriraman et  al. 
[20], attributed the role of HtrA in secretion of recombi-
nant proteins with the mechanism of induction, because 
of HtrA involvement in alternations of bacterial cell wall 
permeability properties. Moreover, mutation of htrA 
gene increased aggregation of cells and therefore reduced 
membrane exposure for inducer, e.g. nisin, affecting acti-
vation of genes involved in a secretion machinery [20]. 
To check, whether the observed pattern was a result of 
action of lactococcal extracellular proteases, we initiated 
the expression and secretion of TRAIL in the presence of 
serine proteases inhibitor, aprotynin. However, the addi-
tion of aprotynin to the culture broth, had no effect on 
the appearance of the two forms of hsTRAIL, suggest-
ing that bacterial extracellular proteases are not involved 
in the cleavage of hsTRAIL. It is worth mentioning that 
the pattern of two bands for hsTRAIL secreted by L. lac-
tis (hsTRAIL+) strain has been detected in every single 
Western blot, even if the native (without protein precipi-
tation) L. lactis (hsTRAIL+) culture broth supernatant 
was electrophoresed (Fig. 5b). Analysis of the amino acid 
sequences performed on the two hsTRAIL protein bands 
showed that the upper (larger) band represents a slightly 
truncated form of hsTRAIL containing 160 amino acid 
(aa) residues, while the lower (smaller) band represents a 
more truncated form of hsTRAIL deprived of 37 aa resi-
dues from the N-terminus of the protein, both having the 
bacterial usp45 leading peptide cut off. It is also worth 
noting that the positive control (rhTRAIL, Peprotech), 
was a protein encoded by the E. coli strain and the fold-
ing nature of hsTRAIL expressed by L. lactis could be 
quite different, therefore, vertical positioning of these 
proteins on the Western blot may not indicate their exact 
molecular size. However, analysis of the mechanism of 
post-translational modifications of hsTRAIL in L. lactis 
bacteria goes beyond the scope of the current paper.
To assess the in vitro cytotoxicity of hsTRAIL we incu-
bated colon cancer cells with supernatants from L. lactis 
(hsTRAIL+) bacteria. In parallel, normal human fibro-
blasts were incubated in the same conditions. Using MTS 
assay to assess cell viability, we observed that hsTRAIL 
produced by recombinant L. lactis (hsTRAIL+) bacte-
ria efficiently and selectively induced apoptosis of can-
cer cells in a dose-dependent manner. When comparing 
antitumor activity of purified and concentrated hsTRAIL, 
obtained from broth culture of nisin-induced L. lactis 
(TRAIL+) with commercial TRAIL probe at the same 
concentration range, we showed almost the same level 
of TRAIL-mediated cytotoxicity against HCT116 human 
colorectal cell line and confirmed the mechanism as 
apoptosis. However, determination of the precise biologi-
cal activity of these two TRAIL protein requires further 
investigations.
Conclusions
In conclusion, our findings document the culture and 
expression conditions enabling production of human sol-
uble TRAIL by recombinant L. lactis strain, which effec-
tively eliminates HCT116 human colon cancer cells via 
apoptosis in vitro. Using L. lactis bacteria, as a live vec-
tor for TRAIL delivery for a potential future treatment 
may have many advantages, e.g. production of proteins 
by non-pathogenic bacteria and local effect of secreted 
therapeutic protein. Further studies using in  vivo mod-
els in human colorectal cancer-bearing mice have been 
already undertaken to provide evidence if the hsTRAIL-
expressing L. lactis bacteria could be used as an effective 
and safe producer of TRAIL for future clinical use.
Methods
Cell cultures
Human colon carcinoma cell line HCT116 was 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA) and maintained according to 
the ATCC’s instructions. Human primary proliferating 
cardiac fibroblasts were obtained from Cell Applica-
tions, Inc. (San Diego, CA). Briefly, HCT116 cells were 
cultured in McCoy’s 5A medium, supplemented with 
10% fetal bovine serum (FBS) and gentamicin (50  µg/
Fig. 8 Quantitative determination of hsTRAIL secretion by L. lactis 
(hsTRAIL+) and L. lactis (hsTRAIL−) bacteria. Supernatants from broth 
culture of L. lactis (hsTRAIL±) bacteria or corresponding lysates of 
bacteria were subjected to ELISA to assess the protein secretion 
efficacy. The bars indicate the mean value ± SD of three independent 
experiments, each performed in triplicates. Differences between the 
groups were calculated using two‑way ANOVA with Tukey’s multiple 
comparisons post‑test. *p < 0.001
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ml) (all from Gibco, Paisley, UK) in a 37  °C humidi-
fied atmosphere with 5%  CO2. Human cardiac fibro-
blasts were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma Aldrich, Saint Louis, MI) 
supplemented with 10% FBS and 1:100 penicillin/strep-
tomycin (all from Life Technologies, Carlsbad, CA) in 
a 37 °C humidified atmosphere with 5%  CO2. The cells 
were regularly tested for Mycoplasma sp. contamina-
tion by PCR-ELISA kit (Roche, Mannheim, Germany) 
and for endotoxin contamination by the Limulus test 
(Charles River Laboratories, Wilmington, MA) accord-
ing to manufacturer’s instruction.
Bacterial cell cultures
Lactococcus lactis NZ9000 host strain, a derivate of L. 
lactis subsp. cremoris MG1363 with regulatory genes 
(nisR, nisK) integrated into the pepN gene of MG1363 
[15], was obtained from MoBiTec (Goettingen, Ger-
many) and cultured in M17 medium (BTL, Lodz, 
Poland) supplemented with 0.5% glucose (POCH, Gli-
wice, Poland). For culture of L. lactis clones harbouring 
secretion plasmid vector pNZ8124 (MoBiTec) and its 
modified derivatives with the human soluble TRAIL-
cDNA placed downstream of the inducible promoter 
PnisA on the plasmid pNZ8124, chloramphenicol 
Fig. 9 Selectivity of hsTRAIL‑induced death to cancer cells. HCT116 cells and human cardiac fibroblasts were incubated for 48 h with increasing 
concentration of hsTRAIL present in supernatant from broth culture of L. lactis (hsTRAIL+). As controls in experimental setup were used: 
corresponding volumes of supernatants from broth culture of L. lactis (hsTRAIL−)—negative control; corresponding concentrations of recombinant 
human TRAIL (Peprotech)—positive control. Viability of cancer cells and non‑malignant, cardiac fibroblasts was assessed by MTS assay. Results are 
presented as % of viability of cells incubated in standard culture medium only. Secreted hsTRAIL remained non‑cytotoxic to fibroblasts (Fig. 9a), 
while decreased viability of cancer cells in a dose‑dependent manner (Fig. 9b). Table below—concentration of hsTRAIL [ng/ml] in specified volume 
of supernatant. The bars indicate the mean value ± SD of three independent experiments, each performed in triplicates. Statistical significance was 
calculated using two‑way ANOVA with Tukey’s multiple comparison post‑test. *p < 0.05, **p < 0.01, ***p < 0.001
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(10  µg/ml; Sigma Aldrich) was added to maintain the 
plasmid.
hsTRAIL‑cDNA cloning
A synthetic human soluble TRAIL-cDNA (hsTRAIL-
cDNA) with optimized codons was designed to fit the 
codon usage pattern (codon bias) of the L. lactis host. 
This synthetic cDNA construct contained 169 codons 
plus stop codon, including 76 original and 94 changed 
codons for those more frequently found in L. lactis highly 
expressed genes. Synthetic hsTRAIL-cDNA construct 
was commercially synthetized by Eurofins Genomic 
(Ebersberg, Germany). Then, constructed hsTRAIL-
cDNA sequence was ligated, using T4 DNA ligase (EurX, 
Gdansk, Poland), to EcoRV and XbaI—linearized plasmid 
vector pN8124 (MobiTec), containing sequence coding 
for signal peptide of lactococcal usp45 gene. Prepared 
pNZ8124-hsTRAIL plasmid vector was transformed into 
the electrocompetent L. lactis NZ9000 host strain cells 
by electroporation, using Gene PulserXcell™ Electropo-
ration System (BioRad, Hercules, CA), according to vec-
tor producer’s instruction (MoBiTec).
Selection of a positive clone of L. lactis harbouring 
recombinant plasmid pNZ8124‑hsTRAIL
Positive clone of L. lactis containing insert for 
hsTRAIL-cDNA after electroporation with plasmid 
vector pNZ8124-hsTRAIL was selected in two-steps. 
First, isolated plasmids were cleaved with EcoRV and 
XbaI restriction enzymes (EurX) and the presence of 
hsTRAIL-cDNA insert was defined by the size of cleaved 
fragments using agarose gel electrophoresis (1.5% aga-
rose gel). In the second step, selected fragments were 
purified from the gel and amplified by PCR method using 
the following primers: 5′-TGG TAC TCG TGG TCG TAG 
CA-3′ sense and 5′-GAA GCT TCG TGG TCC ATG TC-3′ 
antisense (Genomed, Warsaw, Poland). Clone number 3 
was selected as TRAIL-positive, designated as L. lactis 
(hsTRAIL+) and used for further studies.
Optimization of culture conditions for the recombinant L. 
lactis (hsTRAIL+) clone
M17 broth medium (BD Difco, Franklin Lakes, NJ) sup-
plemented with 0.5% glucose (Gluc) and 10  µg/ml of 
chloramphenicol (Cm10), was inoculated with L. lac-
tis (hsTRAIL+) glycerol stock and grown overnight at 
30  °C, without aeration. To optimize conditions for cul-
ture of the recombinant L. lactis clone, the following cul-
ture media were prepared: M17 supplemented with 0.5% 
Gluc, Cm10; M17 supplemented with 0.1% Gluc, 0.1% 
of l-arginine (Arg) and Cm10; M17 supplemented with 
0.3% Gluc, 0.3% Arg and Cm10, and then were inoculated 
with an overnight pre-culture of bacteria in a dilution of 
1:20, and incubated at 30 °C, without aeration. The  OD600 
and pH of the cell cultures were determined after 4 and 
24 h. A 4-h culture period was selected and further used 
for the production of hsTRAIL by L. lactis producer 
(clone no. 3) upon induction with nisin.
Induction of hsTRAIL expression with nisin
For induction of hsTRAIL expression and secretion by 
L. lactis (hsTRAIL+) bacteria, the M17 broth medium 
supplemented with 0.5% Gluc and Cm10 was inocu-
lated with L. lactis (hsTRAIL+) or L. lactis with empty 
vector pNZ8124—L. lactis (hsTRAIL−)—used as a 
negative control. Cultures were diluted 1:40 and grown 
overnight at 30 °C, without aeration. Overnight cultures 
were diluted 1:20 in M17 broth medium supplemented 
with 0.3% Gluc, 0.3% Arg, Cm10 and  ZnSO4 (100  µM) 
and grown for additional 3  h at 30  °C without aeration 
until  OD600 = 0.3–0.4. After incubation, the cultures 
Fig. 10 Lactococcus lactis‑derived hsTRAIL‑induced death of 
human colon cancer HCT116 cells in vitro. HCT116 cells were 
incubated for 48 h with increasing concentrations of hsTRAIL 
in supernatants from broth culture of L. lactis (hsTRAIL+). The 
following controls in experimental setup were used: corresponding 
volumes of supernatants of L. lactis (hsTRAIL−)—negative control; 
corresponding concentrations of recombinant human TRAIL 
(Peprotech)—positive control. Viability of cancer cells was assessed 
by MTS assay. Results are presented as % of viability of cells incubated 
in standard culture medium only. hsTRAIL present in supernatant 
from L. lactis (hsTRAIL+) broth culture decreased viability of cancer 
cells in a dose‑dependent manner, comparable to corresponding 
concentrations of positive control. Table below—concentration of 
TRAIL [ng/ml] in specified volume of supernatant or concentration of 
standard TRAIL formulation (rhTRAIL, Peprotech). The bars indicate the 
mean value ± SD of three independent experiments, each performed 
in triplicates. Statistical significance was calculated using two‑way 
ANOVA with Tukey’s multiple comparison post‑test. *p < 0.05, 
**p < 0.01, ***p < 0.001
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were centrifuged for 30  min at 2800×g at room tem-
perature and the cell pellets were resuspended in 1/4 
volume of M17 supplemented with 0.3% Gluc, 0.3% Arg, 
Cm10,  ZnSO4 (100  µM) and aprotynin (BioShop, Burl-
ington, Canada), as the serine proteases inhibitor, to pre-
vent potential cleavage of expressed hsTRAIL protein, 
and were induced for hsTRAIL expression with nisin 
(MoBiTec). For optimization of induction conditions, the 
cultures were induced with the following concentrations 
of nisin: 10; 25; 35; 50; 80 ng/ml in M17 medium supple-
mented as above. The optimal concentration of aprotynin 
was established experimentally from 2 to 5 µg/ml tested. 
After 4  h of incubation, the  OD600 of the cultures was 
measured to monitor the bacterial growth and then the 
cells were centrifuged for 30 min at 2800×g at 4 °C. Cell-
free supernatants were collected, pH was measured and 
neutralized (if necessary) to pH = 7 with NaOH (POCH, 
Gliwice, Poland). TRAIL samples concentration was per-
formed using disposable The Thermo Scientific™ Pierce™ 
PES 10  K protein concentrators (Pierce Biotechnology, 
Rockford, IL) for centrifugal ultrafiltration, according to 
the manufacturer’s instructions. Concentrated superna-
tants were filtered through low protein-binding filters 
(Merck-Millipore, Burlington, MA), aliquoted and stored 
at − 80 °C until use for further studies.
Isolation of hsTRAIL protein
hsTRAIL was precipitated as total protein content from 
sterile culture supernatants using chloroform–metha-
nol protein extraction method [39]. Briefly, 600  µl of 
methanol was added to 150  µl of culture supernatant 
and vortexed, after which chloroform, at ratio 1:1 to the 
starting volume of the supernatant, was added and vor-
texed again. Next, 450  µl of  H2O was added, and the 
whole suspension was vortexed and centrifuged for 5 min 
at 14,000×g. The top, aqueous layer was removed, then 
600 µl of methanol was added and the mixture was vor-
texed and centrifuged for 10 min at 14,000×g. Methanol 
was removed and the pellet was dried under vacuum 
for 1.5  h, and resuspended in Bacterial Protein Extrac-
tion Reagent (BPER, Thermo Fisher Scientific, Waltham, 
MA) with addition of protease inhibitor cocktail (Pierce, 
Waltham, MA) and stored at − 20 °C until further use.
Western blot analysis of hsTRAIL produced by L. lactis 
(hsTRAIL+) bacteria
The protein samples precipitated from supernatants of L. 
lactis (hsTRAIL±) cultures were used for protein sepa-
ration by the SDS-PAGE electrophoresis and Western 
blot analysis. Protein concentration was measured using 
BCA (Bicinchoninic acid) protein assay kit (Pierce) and 
the equal amounts of the samples were mixed with LDS 
sample buffer (lithium dodecyl sulfate at pH of 8.4, Inv-
itrogen, Carlsbad, CA) and reducing buffer (50  mM 
dithiothreitol—DTT; Invitrogen), incubated at 70  °C for 
10  min and loaded onto 14% SDS-PAGE gel. Recombi-
nant human TRAIL (rhTRAIL; PeproTech, London, UK) 
was used as a positive control. After electrophoresis, sep-
arated proteins were transferred onto the polyvinylidene 
fluoride membrane (PVDF, BioRad) using Trans-Blot 
Turbo Transfer System (BioRad). Subsequently blots were 
blocked for 1 h at room temperature with 5% of nonfat 
milk in TTBS buffer (50 mM Tris–HCl, pH 7.6; 150 mM 
NaCl, 1% Tween-20). The protein bands were detected 
using the following antibodies: primary—mouse anti-
human sTRAIL/Apo2L monoclonal antibodies (dilution 
1:1000; Santa Cruz Biotechnology, Santa Cruz, CA); sec-
ondary—goat anti-mouse HRP-conjugated IgG (dilution 
1:8000; Santa Cruz Biotechnology) and visualized with 
the SuperSignal West Pico Chemiluminescence Substrate 
kit (Pierce) according to the manufacturer’s protocol and 
analysed with KODAK GEL LOGIC 1500 Digital Imaging 
System (KODAK, Rochester, NY).
SYPRO® Ruby Protein gel staining
The protein samples precipitated from supernatants 
of L. lactis (hsTRAIL±) cultures, or crude superna-
tants samples, were used for protein separation by the 
SDS-PAGE electrophoresis. Protein concentration was 
measured using BCA (Bicinchoninic acid) protein assay 
kit (Pierce) and the equal amounts of the samples were 
mixed with LDS sample buffer (lithium dodecyl sulfate at 
pH of 8.4, Invitrogen, Carlsbad, CA) and reducing buffer 
(50  mM dithiothreitol—DTT; Invitrogen), incubated at 
70  °C for 10  min and loaded onto 14% SDS-PAGE gel. 
After electrophoresis,  SYPRO® Ruby Protein gel stain-
ing (Molecular Probes, Eugene, US) was performed to 
detect proteins present in supernatants. The gel was 
(See figure on next page.)
Fig. 11 Induction of apoptosis of colon cancer HCT116 cells by hsTRAIL from supernatant of L. lactis (hsTRAIL+). HCT116 cells were treated with 
supernatants from broth cultures of L. lactis (hsTRAIL±) bacteria and rhTRAIL (positive control) in a corresponding dose of 100 ng/ml for 48 h and 
then stained with FITC‑Annexin V and PI to determine cancer cells apoptosis. HCT116 turned apoptotic after treatment with supernatant of L. lactis 
(hsTRAIL+) bacteria (a, d) in contrast to supernatant of L. lactis (hsTRAIL−) (negative control; c) or medium (b). As positive control, standard TRAIL 
formulation (rhTRAIL, Peprotech) in corresponding concentration was used (e). Dot‑plots. FL1‑H—FITC; FL2‑H—PI. The bars (a) indicate the mean 
value ± SD of three independent experiments, each performed in triplicates. Differences between the groups were calculated using two‑way 
ANOVA with Tukey’s multiple comparisons post‑test. *p < 0.05
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fixed (50% methanol, 7% acetic acid) for 30 min, stained 
overnight with  SYPRO® Ruby gel stain, washed in wash 
solution (10% methanol, 7% acetic acid) for 30 min. and 
rinse twice in ultrapure water. The gel was analyzed using 
ChemiDoc™ Imaging system (BioRad).
Sequencing TRAIL protein by mass spectrometry (LC–MS/
MS)
The visualized SDS-PAGE bands (Coomassie Bril-
liant Blue staining) were cut out and proteins were 
reduced, alkylated, and digested according to the pro-
tocol described previously [40]. Peptides were analyzed 
with the use of a Q-Exactive mass spectrometer (Thermo 
Fisher Scientific) coupled with nano-HPLC (UltiMate 
3000 RSLCnano System, Thermo Fisher Scientific) as 
previously described with minor modifications [41]. Pep-
tides were separated using a 90 min gradient of acetoni-
trile from 2 to 40% in the presence of 0.05% formic acid. 
The Top 8 method was used for mass spectrometry meas-
urement with full MS and MS/MS resolution of 70,000 
and 35,000 respectively. Database searching of RAW 
files was performed in Proteome Discoverer 1.4 (Thermo 
Fisher Scientific) MASCOT 2.5.1 (Matrix Science Ltd, 
London, UK) was used for database searching against 
the common Repository of Adventitious Proteins (cRAP) 
database containing the sequences of recombinant tumor 
necrosis factor ligand superfamily member 10 (TRAIL), 
lactococcal protein usp45 and common contaminants. 
The following search parameters were applied: enzyme 
specificity—trypsin; permitted number of missed cleav-
ages—1; fixed modification—carbamidomethylation 
(C); variable modifications—oxidation (M), deamidation 
(NQ); precursor mass tolerance—± 10  ppm; fragment 
mass tolerance—± 20 mmu. Identifications with a score 
value over 80 were accepted.
Assessment of TRAIL secretion efficacy
Induction of hsTRAIL secretion was performed as 
described above. The L. lactis cells in broth culture were 
centrifuged for 30 min at 2800×g at 4 °C and extraction 
of protein from bacterial cells pellet was performed. The 
cells were resuspended in Bacterial Protein Extraction 
Reagent (BPER, Thermo Fisher Scientific) with addition 
of protease inhibitor cocktail (Pierce), 10  U of DNase-
I and 5.6 mg/ml of lysozyme (both from Thermo Fisher 
Scientific), then incubated for 1  h at 37  °C and 10  min. 
at 70  °C to inhibit the enzymes. After centrifugation 
(10  min., 15,000×g, RT) cell lysates were collected and 
stored at −  80  °C until further use. To assess the con-
centration of hsTRAIL in the lysate from recombinant L. 
lactis (hsTRAIL+) bacteria and secreted to the broth cul-
ture medium during induction, ELISA for human soluble 
TRAIL (LSBio™, Seattle, WA) was performed according 
to the manufacturer’s instructions. The absorbance was 
measured at 450 nm and 570 nm (wavelength correction) 
using microplate reader ELx 800NB (BIO-TEK INSTRU-
MENTS, Winooski, VT).
Cell viability assay
Cytotoxic activity of hsTRAIL from the culture super-
natant of L. lactis (hsTRAIL+) against human colon 
cancer HCT116 cells and human cardiac fibroblasts was 
determined using 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium (MTS) assay (CellTiter  96®  AQueous One Solution 
Cell Proliferation Assay, Promega, Madison, WI). Briefly, 
HCT116 cells and human cardiac fibroblasts were seeded 
onto flat-bottom 96-well plates (Sarstedt, Numbrecht, 
Germany) at a density of  104/5  ×  103 cells per well in 
McCoy’s 5A/DMEM medium, respectively, containing 
2% FBS. After 20 h for cell attachment, the supernatant 
from the culture of L. lactis (hsTRAIL+) was added to 
the cells in the dilutions corresponding to the concen-
trations of hsTRAIL: 25; 50; 75; 100  ng/ml, respectively 
(measured using ELISA Kit (LSBio™, Seattle, WA). As a 
negative control, the supernatant from the cultures of L. 
lactis (hsTRAIL−) was added to the cells in correspond-
ing volumes. As a positive control, recombinant human 
TRAIL (rhTRAIL; PeproTech) was used in the same range 
of concentrations. After 48 h of incubation 20 µl per well 
of MTS (CellTiter  96®  AQueous One Solution Cell Prolif-
eration Assay, Promega) dye solution was added directly 
into the culture wells and incubated for additional 2  h. 
The quantity of formazan product, directly proportional 
to the number of living cells in culture, was detected by 
absorbance measurement at 490 nm with a 96-well plate 
reader  (Spark® Tecan, Mannedorf, Switzerland).
Detection of apoptosis by flow cytometry
Apoptosis of HCT116 cells was determined using FITC-
Annexin V Apoptosis Detection kit (BD Pharmingen, New 
Jersey, US) according to the to the manufacturer’s instruc-
tions. Briefly, HCT116 cells were seeded onto flat-bottom 
24-well plate (Sarstedt) at a density of  105 cells per well in 
McCoy’s 5A medium containing 2% FBS. After 20 h for cell 
attachment, the supernatant from the culture of L. lactis 
(hsTRAIL+) was added to the cells in the dilutions corre-
sponding to the concentration of hsTRAIL 100 ng/ml. As 
a negative control, the supernatant from the cultures of L. 
lactis (hsTRAIL−) was added to the cells in corresponding 
volume. As a positive control, recombinant human TRAIL 
(rhTRAIL; PeproTech) was used in the same concentra-
tion. After 48 h of incubation, the cells were washed twice 
in ice-cold PBS, trypsynized and cell pellets were respus-
pended in 1× Annexin V Binding Buffer (0.01 M Hepes/
NaOH (pH 7.4), 0.14  M NaCl, 2,5  mM  CaCl2). The cells 
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were stained with Annexin V-FITC and PI for 15 min at RT 
in the dark, followed by FACS analysis using FACSCalibur 
(Becton–Dickinson Immunocytometry System, Palo Alto, 
CA) by using CellQuest (version 3.1) software.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
Software version 4.00 (2003). Statistical significance was 
calculated using two-way ANOVA with Tukey’s multiple 
comparisons post-test. *p < 0.05, **p < 0.01, ***p < 0.001. The 
data from each assay are representative for 3–5 independ-
ent experiments.
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